OCUGEN, INC. (OCGN) Current Ratio
- Current ratio · latest quarter: Value 0.80×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.80× | Current assets / current liabilities. $106.72M ÷ $133.08M ≈ 0.80× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 106.72M USD | Assets, Current |
| Current obligations | 133.08M USD | Liabilities, Current |
| Cash and equivalents | 100.05M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.14M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 20.00K USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $106.72M | $133.08M | $100.05M | (m) | (m) | (m) | $5.14M | $20.00K | 0.80× |
| 2026-03-31 | $38.55M | $20.71M | $31.90M | (m) | (m) | (m) | $3.24M | $5.00M | 1.86× |
| 2025-12-31 | $24.34M | $23.04M | $18.57M | (m) | (m) | (m) | $6.20M | $1.25M | 1.06× |
| 2025-09-30 | $37.64M | $20.36M | (m) | (m) | (m) | (m) | $4.57M | $0.00 | 1.85× |
| 2025-06-30 | $32.88M | $17.99M | (m) | (m) | (m) | (m) | $4.24M | $0.00 | 1.83× |
| 2025-03-31 | $43.96M | $16.89M | $37.80M | (m) | (m) | (m) | $3.22M | $0.00 | 2.60× |
| 2024-12-31 | $61.68M | $21.59M | (m) | (m) | (m) | (m) | $4.24M | $1.33M | 2.86× |
| 2024-09-30 | $40.67M | $15.76M | (m) | (m) | (m) | (m) | $1.49M | $1.32M | 2.58× |
| 2024-06-30 | $18.62M | $17.97M | $15.70M | (m) | (m) | (m) | $3.39M | $1.31M | 1.04× |
| 2024-03-31 | $30.00M | $16.05M | $26.38M | (m) | (m) | (m) | $1.73M | $1.30M | 1.87× |
| 2023-12-31 | $42.97M | $17.09M | (m) | (m) | (m) | (m) | $3.17M | $0.00 | 2.51× |
| 2023-09-30 | $56.56M | $19.73M | $53.48M | $0.00 | (m) | (m) | $2.92M | $1.28M | 2.87× |
| 2023-06-30 | $73.45M | $24.50M | $70.58M | $0.00 | (m) | (m) | $3.88M | $1.27M | 3.00× |
| 2023-03-31 | $84.40M | $26.58M | $68.26M | $8.46M | (m) | (m) | $8.09M | $1.26M | 3.18× |
| 2022-12-31 | $98.49M | $28.53M | $77.56M | $13.37M | (m) | (m) | $8.06M | (m) | 3.45× |
| 2022-09-30 | $107.50M | $24.52M | $101.60M | $0.00 | (m) | (m) | $6.46M | $0.00 | 4.38× |
| 2022-06-30 | $122.57M | $17.96M | $115.00M | $0.00 | (m) | (m) | $5.92M | $0.00 | 6.82× |
| 2022-03-31 | $138.03M | $13.30M | $129.77M | $0.00 | (m) | (m) | $3.90M | $0.00 | 10.38× |
| 2021-12-31 | $102.65M | $7.00M | $94.96M | $0.00 | (m) | (m) | $2.31M | (m) | 14.66× |
| 2021-09-30 | $113.45M | $6.23M | $107.35M | (m) | (m) | (m) | $2.10M | (m) | 18.21× |
| 2021-06-30 | $121.63M | $4.84M | $115.64M | (m) | (m) | (m) | $802.00K | (m) | 25.13× |
| 2021-03-31 | $51.36M | $4.28M | $44.79M | (m) | (m) | (m) | $1.04M | (m) | 12.00× |
| 2020-12-31 | $25.88M | $3.61M | $24.04M | (m) | (m) | (m) | $395.00K | (m) | 7.16× |
| 2020-09-30 | $19.76M | $4.13M | $19.11M | (m) | (m) | (m) | $222.34K | (m) | 4.78× |
| 2020-06-30 | $22.89M | $7.04M | $14.97M | (m) | (m) | (m) | $507.86K | (m) | 3.25× |
| 2020-03-31 | $11.36M | $3.31M | $3.19M | (m) | (m) | (m) | $1.55M | (m) | 3.43× |
| 2019-12-31 | $15.77M | $4.54M | $7.44M | (m) | (m) | (m) | $1.90M | (m) | 3.47× |
| 2019-09-30 | $22.82M | $35.41M | $15.30M | (m) | (m) | (m) | $5.79M | (m) | 0.64× |
| 2019-06-30 | $3.24M | $8.89M | $678.49K | (m) | (m) | (m) | $5.26M | (m) | 0.36× |
| 2019-03-31 | $8.14M | $2.32M | $7.38M | (m) | (m) | (m) | $1.10M | (m) | 3.51× |
| 2018-12-31 | $1.94M | $14.11M | $1.63M | (m) | (m) | (m) | $3.28M | (m) | 0.14× |
| 2018-09-30 | $6.02M | $8.94M | $5.19M | (m) | (m) | (m) | $1.69M | (m) | 0.67× |
| 2018-06-30 | $9.65M | $11.66M | $8.77M | (m) | (m) | (m) | $2.21M | (m) | 0.83× |
| 2018-03-31 | $16.36M | $8.42M | $15.51M | (m) | (m) | (m) | $1.36M | (m) | 1.94× |
| 2017-12-31 | $8.18M | $3.81M | $7.08M | $900.00K | (m) | (m) | $776.00K | (m) | 2.15× |
| 2017-09-30 | $12.88M | $2.91M | $10.80M | $1.82M | (m) | (m) | $827.00K | (m) | 4.42× |
| 2017-06-30 | $18.84M | $3.83M | $10.56M | $7.98M | (m) | (m) | $1.62M | (m) | 4.92× |
| 2017-03-31 | $24.67M | $3.90M | $16.37M | $8.00M | (m) | (m) | $1.89M | (m) | 6.33× |
| 2016-12-31 | $32.08M | $5.17M | $31.91M | (m) | (m) | (m) | $1.59M | (m) | 6.20× |
| 2016-09-30 | $38.20M | $7.21M | $37.99M | (m) | (m) | (m) | $1.67M | (m) | 5.30× |
| 2016-06-30 | $16.28M | $6.72M | $15.93M | (m) | (m) | (m) | $1.77M | (m) | 2.42× |
| 2016-03-31 | $23.36M | $5.97M | $22.90M | (m) | (m) | (m) | $1.71M | (m) | 3.91× |
| 2015-12-31 | $31.24M | $6.36M | $30.91M | (m) | (m) | (m) | $2.02M | (m) | 4.91× |
| 2015-09-30 | $38.09M | $6.69M | $37.72M | (m) | (m) | (m) | $2.00M | (m) | 5.69× |
| 2015-06-30 | $46.12M | $6.69M | $45.22M | (m) | (m) | (m) | $2.34M | (m) | 6.90× |
| 2015-03-31 | $54.01M | $7.50M | $53.18M | (m) | (m) | (m) | $3.29M | (m) | 7.20× |
| 2014-12-31 | $59.32M | $7.60M | $58.53M | (m) | (m) | (m) | $4.89M | (m) | 7.81× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |